{"id":44833,"date":"2022-06-08T12:01:44","date_gmt":"2022-06-08T10:01:44","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\/"},"modified":"2022-06-08T12:01:44","modified_gmt":"2022-06-08T10:01:44","slug":"atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\/","title":{"rendered":"Atom Bioscience to Update Clinical Development of New Drug to Treat Gout at BIO International Convention, June 13 \u2013 16, 2022, San Diego, CA"},"content":{"rendered":"
\n

\nPhase 2a results show the orally administered ABP-671 significantly reduced uric acid levels without adverse side effects of existing drugs<\/i>\n<\/p>\n

JIANGSU, China–(BUSINESS WIRE)–Atom Bioscience, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today it will update its clinical development of ABP-671, the company\u2019s new oral drug for chronic gout, during a presentation at the BIO International Convention<\/a> on June 13 \u2013 16, 2022, at the San Diego Convention Center, San Diego, CA. The convention is the world\u2019s largest gathering of biotech executives, scientists and academic researchers.\n<\/p>\n

<\/a><\/p>\n

\nRoy J. Wu, Senior Vice President of Business Development, will make the Atom Bioscience company presentation<\/a> Monday, June 13, 12:45 pm \u2013 1 pm (PDT) in Company Presentation Theater 1 on the Exhibit Floor of the San Diego Convention Center. In addition to updating clinical development of ABP-671, the company\u2019s lead drug candidate, Mr. Wu will review Atom\u2019s pipeline of other best-in-class small molecule therapeutics.\n<\/p>\n

\nGout is one of the most common types of inflammatory arthritis affecting 55 million people worldwide and more than 9.3 million in the US. It is caused by a long-term condition known as hyperuricemia, the excessive build-up of uric acid in the blood (> 7 mg\/dL).\n<\/p>\n

\nAtom\u2019s Phase 2a randomized double-blind, placebo-controlled clinical trial in Australia of ABP-671, a second generation oral URTA1 inhibitor, achieved its primary endpoint of reducing uric acid to less than 6 mg\/dL. Significantly, no safety concerns were reported. Based on these findings, the company expects to launch global pivotal Phase 3 studies shortly.\n<\/p>\n

\nTo learn more about chronic gout, see video from expert Dr. Lawrence Edwards, Vice Chairman and Professor, Department of Medicine, University of Florida. Dr. Edwards is an Atom Bioscience adviser. https:\/\/atombp.us\/video-causes-of-gout\/<\/a>\n<\/p>\n

\nAbout Atom Bioscience
\n
<\/b>Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd.) is a fast-growing innovative drug company, focused on development of best in class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company\u2019s lead product, ABP-671, is in clinical development for treatment of chronic gout. For more information please visit: https:\/\/atombp.us\/<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact:
\n
Daniel Eramian
\n
Opus Biotech Communications
\n
http:\/\/opusbiotech.com\/<\/a>
425-306-8716<\/p>\n

Business Development Contact:
\n
Roy J. Wu, MBA
\n
Sr. Vice President, Business Development
\n
Atom Bioscience and Pharmaceutical Co., Ltd
\n
Email: roy.wu@atombp.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Phase 2a results show the orally administered ABP-671 significantly reduced uric acid levels without adverse side effects of existing drugs JIANGSU, China–(BUSINESS WIRE)–Atom Bioscience, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today it will update its clinical development of ABP-671, the company\u2019s new oral drug for chronic gout, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44833","6":"format-standard","7":"category-industry"},"yoast_head":"\nAtom Bioscience to Update Clinical Development of New Drug to Treat Gout at BIO International Convention, June 13 \u2013 16, 2022, San Diego, CA - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Atom Bioscience to Update Clinical Development of New Drug to Treat Gout at BIO International Convention, June 13 \u2013 16, 2022, San Diego, CA - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Phase 2a results show the orally administered ABP-671 significantly reduced uric acid levels without adverse side effects of existing drugs JIANGSU, China–(BUSINESS WIRE)–Atom Bioscience, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today it will update its clinical development of ABP-671, the company\u2019s new oral drug for chronic gout, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-08T10:01:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220608005064\/en\/1478332\/21\/Atom_Bioscience_Logo_%281%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Atom Bioscience to Update Clinical Development of New Drug to Treat Gout at BIO International Convention, June 13 \u2013 16, 2022, San Diego, CA\",\"datePublished\":\"2022-06-08T10:01:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\\\/\"},\"wordCount\":398,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220608005064\\\/en\\\/1478332\\\/21\\\/Atom_Bioscience_Logo_%281%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\\\/\",\"name\":\"Atom Bioscience to Update Clinical Development of New Drug to Treat Gout at BIO International Convention, June 13 \u2013 16, 2022, San Diego, CA - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220608005064\\\/en\\\/1478332\\\/21\\\/Atom_Bioscience_Logo_%281%29.jpg\",\"datePublished\":\"2022-06-08T10:01:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220608005064\\\/en\\\/1478332\\\/21\\\/Atom_Bioscience_Logo_%281%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220608005064\\\/en\\\/1478332\\\/21\\\/Atom_Bioscience_Logo_%281%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Atom Bioscience to Update Clinical Development of New Drug to Treat Gout at BIO International Convention, June 13 \u2013 16, 2022, San Diego, CA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Atom Bioscience to Update Clinical Development of New Drug to Treat Gout at BIO International Convention, June 13 \u2013 16, 2022, San Diego, CA - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\/","og_locale":"en_US","og_type":"article","og_title":"Atom Bioscience to Update Clinical Development of New Drug to Treat Gout at BIO International Convention, June 13 \u2013 16, 2022, San Diego, CA - Pharma Trend","og_description":"Phase 2a results show the orally administered ABP-671 significantly reduced uric acid levels without adverse side effects of existing drugs JIANGSU, China–(BUSINESS WIRE)–Atom Bioscience, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today it will update its clinical development of ABP-671, the company\u2019s new oral drug for chronic gout, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-08T10:01:44+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220608005064\/en\/1478332\/21\/Atom_Bioscience_Logo_%281%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Atom Bioscience to Update Clinical Development of New Drug to Treat Gout at BIO International Convention, June 13 \u2013 16, 2022, San Diego, CA","datePublished":"2022-06-08T10:01:44+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\/"},"wordCount":398,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220608005064\/en\/1478332\/21\/Atom_Bioscience_Logo_%281%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\/","url":"https:\/\/pharma-trend.com\/en\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\/","name":"Atom Bioscience to Update Clinical Development of New Drug to Treat Gout at BIO International Convention, June 13 \u2013 16, 2022, San Diego, CA - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220608005064\/en\/1478332\/21\/Atom_Bioscience_Logo_%281%29.jpg","datePublished":"2022-06-08T10:01:44+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220608005064\/en\/1478332\/21\/Atom_Bioscience_Logo_%281%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220608005064\/en\/1478332\/21\/Atom_Bioscience_Logo_%281%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/atom-bioscience-to-update-clinical-development-of-new-drug-to-treat-gout-at-bio-international-convention-june-13-16-2022-san-diego-ca\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Atom Bioscience to Update Clinical Development of New Drug to Treat Gout at BIO International Convention, June 13 \u2013 16, 2022, San Diego, CA"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44833"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44833\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}